Introduction {#S1}
============

To date, more then 100 chemical modifications have been described in non-coding and protein coding RNAs (see The RNA Modification database^[1](#footnote1){ref-type="fn"}^). The majority of them occur in transfer RNA (tRNA) and ribosomal RNA (rRNA), while a minority of them occur in messenger RNAs (mRNA) and long non-coding RNAs (lncRNAs). In all cases RNA modifications may play important role in RNA folding, stability and function; in view of the fact that, similarly to epigenetics, they can affect gene expression without changing the sequence of the RNA molecules, they are now referred to as "epitranscriptomics." In metazoan, *N*^6^-methyladenosine (m^6^A) is the more abundant internal modification in mRNAs and lncRNAs and plays relevant roles in several steps of gene expression, including splicing, export, stability, and translation. Notably, m^6^A modification is present in all three different phylogenetic domains, Eukaya, Bacteria, and Archea ([@B9]), and is also present in viral RNAs ([@B34]) where it has important regulatory functions ([@B46]). In analogy with DNA and histone modifications, m^6^A is a dynamic mark. It is installed by writers, removed by erasers and recognized by reader proteins. Despite its discovery in the early 1970s ([@B13]; [@B56]; [@B1]), the precise function of m^6^A residues in gene expression regulation remained elusive until recently with the development of high throughput methodologies for mapping of m^6^A residues in the whole transcriptome ([@B14]; [@B48]; [@B40]). These methods used specific immunoprecipitation of m^6^A modified RNAs coupled to RNA sequencing. There are currently two different methodologies. The first one was developed by two independent groups (referred to as m^6^A-Seq or MeRIP-seq) and sequences immunoprecipitated m^6^A RNA fragment of about 200 nt, thus, does not allow for mapping of m^6^A residues at single-nucleotide resolution ([@B14]; [@B48]). The second one (referred to as miCLIP), uses UV cross-linking to covalently bind the anti m^6^A antibody to modified RNAs, which induces mutation and truncation during reverse transcription, allowing for identification of single modified nucleotides within RNA species ([@B40]). m^6^A in mRNAs and lncRNAs can be installed by two independent complexes ([Table 1](#T1){ref-type="table"}): the heterodimeric complex of METTL3/METTL14 (methyltransferase-like protein 3 and 14), also referred to as MAC (m^6^A-METTL Complex), and the homodimeric complex of METTL16 (methyltransferase-like protein 16) (reviewed in [@B84]; [@B35]). The MAC complex methylates adenosine during transcriptional elongation within the consensus motif RRACH (R = A/G; H = A/C/U), and is assisted in adenine selection by a multiprotein complex called MACOM (m^6^A-METTL-associated complex) composed of Wilms tumour 1-associated protein (WTAP), Vir-like m^6^A methyltransferase-associated (VIRMA), Cbl proto-oncogene like 1 (CBLL1, also known as Hakai), RNA-binding motif 15 (RBM15) or its paralog RBM15B, and zinc finger CCCH-type containing 13 (ZC3H13) proteins ([@B35]) ([Table 1](#T1){ref-type="table"}). The METTL3 is the catalytic component of the complex while METTL14 is required for RNA binding and stabilization. Recently, METTL14 was also found to interact with histone H3 trimethylation at Lys36 (H3K36me3), a marker for RNA polymerase II (RNA pol II) transcription elongation, thus ensuring modification of nascent RNAs in both intronic and exonic regions ([@B27]). However, m^6^A residues in mature mRNA molecules follow precise distribution and are enriched near the stop codon and untranslated regions. On the other hand, the METTL16 complex acts on a specific stem--loop structure of RNA containing the UACAGAGAA sequence. This complex acts on only a few percentages on methylated mRNAs and lncRNAs. However, between targeted RNAs, there is the human *S*-adenosylmethionine (SAM) synthetase MAT2A ([@B55]; [@B61]; [@B68]), which regulates cellular levels of the methyl donor SAM. Therein, METTL16 can regulate the activity of all cellular methyltransferases, including METTL3/MELL14. Moreover, it is also responsible for the methylation in the spliceosomal U6 small nuclear RNA (snRNA).

###### 

Human m^6^A proteins.

  **Protein**          **Function**                                                 **References**
  -------------------- ------------------------------------------------------------ ----------------
  *Writers*                                                                         
  METTL3               Installs m^6^A residues in mRNAs and lncRNAs                 [@B41]
  METTL14              Cooperates with METTL3 in m^6^A deposition                   [@B41]
  METTL16              Installs m^6^A in U6 snRNA and few mRNAs and lncRNAs         [@B55]; [@B68]
  *Erasers*                                                                         
  FTO                  Remove m^6^A and m^6^Am from mRNA, and m^1^A from tRNA       [@B29]
  ALKBH5               Remove m^6^A from mRNA                                       [@B85]
  *Regulators*                                                                      
  WTAP                 Regulates m^6^A installation by the METTL3/METTL14 complex   [@B57]
  VIRMA                Regulates m^6^A installation by the METTL3/METTL14 complex   [@B32]; [@B80]
  CBLL1                Regulates m^6^A installation by the METTL3/METTL14 complex   [@B70]; [@B80]
  RBM15                Regulates m^6^A installation by the METTL3/METTL14 complex   [@B32]
  ZC3H13               Regulates m^6^A installation by theMETTL3/METTL14 complex    [@B32]; [@B70]
  *Direct readers*                                                                  
  ABCF1                Stimulates cap-independent translation                       [@B12]
  eIF3                 Stimulates cap-independent translation                       [@B47]
  HNRNPA2B1            Stimulates microRNA processing                               [@B2]
  IGF2BPs              Increase mRNA stability                                      [@B26]
  YTHDC1               Stimulates splicing and mRNA export                          [@B75]; [@B58]
  YTHDC2               Stimulates mRNA decay and translation                        [@B25]; [@B71]
  YTHDF1               Stimulates translation                                       [@B65]
  YTHDF2               Stimulates mRNA decay                                        [@B67]
  YTHDF3               Stimulates mRNA decay and translation                        [@B38]; [@B60]
  *Indirect readers*                                                                
  FMR1                 Inhibits translation                                         [@B17]
  HNRNPC               Regulates splicing                                           [@B42]
  *m^6^A repelled*                                                                  
  ELAVL1               Increases mRNA stability                                     [@B67]
  G3BPs                Increases mRNA stability                                     [@B17]

m^6^A modification can be removed by two demethylase enzymes belonging to the AlkB family of the Fe(II) and α-ketoglutarate-dependent dioxygenases: ALKBH5 (alkB homolog 5) and FTO (fat-mass and obesity associated protein) ([@B84]) ([Table 1](#T1){ref-type="table"}). The first one is specific for m^6^A removal while the second can also demethylate *N^6^, 2-O-dimethyladenosine* (m^6^Am), which is installed in mRNA if the first transcribed nucleotide is adenosine, and *N*^1^-methyladenosine (m^1^A) in tRNA ([@B69]).

Although m^6^A modification does not prevent Watson-Crick base pairing of A-U nucleotides, m^6^A residues can affect tertiary interactions involving Hoogsteen base pairs that use the N^6^ atom of A for H-bond ([@B46]). Therein, m^6^A residues within RNA molecules can produce local changing in the RNA structure that can alter RNA folding and affect the interaction with proteins and RNAs ([@B46]; [@B42]; [@B17]). However, the function of m^6^A modifications in gene expression regulation is mainly mediated by m^6^A readers (reviewed in [@B54]) ([Table 1](#T1){ref-type="table"}). Proteins of the YT521-B homology (YTH) domain family were the first to be identified. In humans, there are five members: the nuclear YTHDC1, and the cytoplasmic YTHDC2, YTHDF1, YTHDF2, and YTHDF3. Mechanistically, YTHDC1 binding in the nucleus regulates alternative splicing and promotes RNA export while YTHDF2 binding stimulates mRNA decay and YTHDF1 binding promotes translation. The YTHDF3 reader can cooperate with both YTHDF1 and YTFDF2 on modified mRNA while in circular RNAs it can promote translation independently from other YTH proteins. Additional readers, lacking the YTH domains, have been also identified, including the translational regulators eIF3 and ABCF1, which positively regulate translation of modified mRNA and the insulin-like growth factor mRNA-binding proteins IGFBP-1, -2 and- 3, which enhance RNA stability and translation ([@B26]). Therein, once installed, m^6^A modifications can produce several different outputs on the regulation of specific RNAs which are not easily predictable.

Notably, m^6^A plays an important role in embryonic stem cells (ESCs) by controlling cell fate transition and deletion of METTL3 and METTL16 in mouse results in embryonic lethality, indicating essential function for m^6^A modification in the regulation of gene expression programs required for embryo development ([@B5]; [@B66]; [@B21]; [@B6]; [@B45]). Moreover, m^6^A plays also important role in mouse adult brain, by regulating synaptic function and stress-induced responses ([@B18]; [@B33]), and in the hematopoietic system, by controlling stem cell differentiation and homeostasis ([@B43]; [@B64]; [@B79]). Even if most of the m^6^A studies focused on its direct role on mRNA function, recent evidences showed that m^6^A can also regulate the synthesis and function of microRNAs and lncRNAs. In addition, microRNAs and lncRNAs can also influence the function of m^6^A modification in mRNAs. Here, we review the impact of m^6^A on the regulation of these non-coding RNAs and we discuss the interplay between m^6^A, microRNAs and lncRNAs in cell development and disease.

Impact of Epitranscriptomics on MicroRNAs Biogenesis and Function {#S2}
=================================================================

MicroRNAs (miRNAs) are endogenously encoded short RNAs (∼21 nucleotides, nt) that are produced from long primary transcripts (pri-miRNA) transcribed by RNA Pol II (reviewed in [@B4]). More than 50% of human miRNAs are encoded in introns of coding and non-coding pre-mRNAs and are connected to the expression of their host genes. The pri-miRNA is cleaved co-transcriptionally by a protein complex, named Microprocessor, containing the nuclear RNase III-type endonuclease *Drosha* and the DGCR8 (DiGeorge syndrome critical region gene 8) protein. The recognition of the pri-miRNA by the Microprocessor requires a stem--loop structure formed by the mature miRNA and single-stranded regions flanking the stem--loop. The cleavage by Drosha produces a stem--loop pre-miRNA of about 70 nt that is then recognized and exported to the cytoplasm by the transport receptor Exportin 5. In the cytoplasm, the pre-miRNA is cleaved by the RNase III-type endonuclease Dicer, releasing the miRNA duplex. One strand is then incorporated into the silencing complex containing one Argonaute (AGO) protein (in human AGO1, AGO2, AGO3, and AGO4) and the TNRC6 protein (also called GW182). The miRNA directs the Ago complex to its target mRNAs through perfect complementarity between sequences in the 3′ì untranslated region (3ì-UTR) and a stretch of 6 nucleotides (from nucleotides 2 to 7) in the 5′ region of the miRNA, also referred to as "seed." The Ago proteins recruit TNRC6 protein, which stimulates mRNA deadenylation by interacting with deadenylase complexes and, consequently, produces mRNA destabilization and translational repression ([@B30]; [@B4]). In addition, TNRC6 also recruits DDX6, a helicase that enhances both the decay and translational repression of target mRNAs ([@B30]; [@B4]). m^6^A modification may affect microRNA synthesis and function at multiple levels ([Figure 1A](#F1){ref-type="fig"}). A strong correlation between m^6^A residues in the 3′-UTR and miRNA-binding sites has been identified ([@B48]). This has suggested the existence of a functional interaction between m^6^A modification and miRNAs targeting. In particular, the presence of m^6^A residues within the complementary region between the 3′-UTR and the miRNA seed might destabilize A-U pairing, thus decreasing duplex stability and affecting miRNA interaction. However, even if alterations in miRNA binding might contribute to some of the observed effects of m^6^A modification, the impact of m^6^A modifications within mRNAs on miRNA targeting is still not clear. On the other hand, m^6^A can also affect miRNA synthesis. m^6^A marks are deposited co-transcriptionally on a set of pri-miRNA molecules and are read by the HNRNPA2B1 proteins that, in turn, stimulate nuclear miRNA processing by recruiting the Microprocessor component DGCR8 ([@B2], [@B3]). Therein, alteration in m^6^A deposition may unbalance cellular miRNA levels. Moreover, upon acute temperature stress, the METTL3/METL14 complex can co-transcriptionally recruit the DGCR8 protein on stem--loop structures present in heat-shock genes, independently from the presence of an embedded precursor microRNA. Thus, promoting their subsequent nuclear degradation by the microprocessor complex ([@B31]). In view of the recent discovery of the association of METTL14 with chromatin during transcriptional elongation ([@B27]), we can speculate that the METTL3/METTL14 complex may contribute to the co-transcriptional recruitment of the Microprocessor complex on pri-miRNA transcripts. In addition, it has also been shown that, in hepatocellular carcinoma (HCC), METTL14 can directly recruit DCGR8 on the m^6^A modified pri-miRNA encoding for oncosuppressor miR-126a ([@B44]). In particular, low levels of METTL14 in HCC are associated with low levels of miR-126a and increased metastatic capacity ([@B44]). More importantly, ectopic expression of miR-126a in HCC cells ameliorated the metastatic phenotype induced by METTL14 downregulation ([@B44]).

![Impact of epitranscriptomics on microRNAs biogenesis and function. **(A)** m^6^A stimulates microRNA processing by recruiting the Drosha cofactor DGCR8 by the m^6^A reader HNBRPA2B1 ([@B2], [@B3]) or, in the case of the miR-126a, by direct interaction with METTL14 ([@B44]). **(B)** During aging of peripheral blood mononuclear cells (PBMCs), AGO2 and, eventually, miRNA levels are decreased by higher m^6^A modification of AGO2 mRNA. This results in enhanced mRNA decay that is very likely mediated by the YTHDF2 reader ([@B49]).](fcell-07-00116-g001){#F1}

Another example highlighting the role m^6^A modification on miRNAs processing has been recently reported for miR-25-3p. Zang and colleagues indeed described the impact of cigarette smoking on miR-25-3p maturation by m^6^A modification in pancreatic ductal adenocarcinoma ([@B82]). In this manuscript, the authors described how the cigarette smoking induced the upregulation of METTL3 expression by affecting METTL3 promoter epigenetic regulation. This results in a METTL3-dependent modification of pri-miR-25-3p and an increase of miR-25-3p processing. The induction of miR-25-3p affects the expression of its target PH domain leucine-rich-repeats protein phosphatase 2 (PHLPP2), with an consequential impact on the AKT-p70S6K signaling pathway ([@B82]). These results suggest that a METTL3-miR-25-3p-PHLPP2-AKT regulatory axis could be relevant for the transformation process induced by cigarette smoking in pancreatic tissue.

Interestingly, an additional mechanism leading to the modulation of m^6^A miRNAs modification is represented by the DDX3-dependent network. Indeed, DDX3, a member of the family of DEAD-box RNA helicases, has been shown to be able to interact with the RNA m^6^A demethylases, such as ALKBH5, resulting in m^6^A RNA demethylation. With specific regard to miRNAs, DDX3, thanks to its ability to also interact with AGO2 protein, may contribute to miRNAs demethylation. In summary, the functional contribution of DDX3 to the control of cell growth and proliferation may be at least in part mediated by its interaction with ALKBH5 and AGO2, relevant for the demethylation of mRNAs and miRNAs ([@B59]).

miRNA levels can also be controlled by m^6^A modification of AGO2 mRNA ([Figure 1B](#F1){ref-type="fig"}). In a study performed on human peripheral blood mononuclear cells (PBMCs) from young and old donors, the AGO2 mRNA was found highly m^6^A methylated in young PBMCs and this correlated with a lower level of AGO2 mRNA in old PBMCs during aging ([@B49]). AGO2 levels are important for both miRNA synthesis and function. Indeed, a lower level of AGO2 in old PBMCS resulted in an altered level of miRNA expression ([@B49]), indicating that m^6^A modification on AGO2 mRNA contributes to cellular aging by regulating global miRNAs synthesis.

Impact of Epitranscriptomics on LncRNA Regulation and Functions {#S3}
===============================================================

LncRNAs are generally defined as transcripts longer than 200 nt without coding potential (reviewed in [@B20]). The human genome contains 16,193 genes encoding for lncRNAs (Gencode v30), which can produce more than 30,000 lncRNA transcripts. The majority of lncRNAs, but not all, share several features with coding mRNAs; they are 5′ capped, spliced and, in most of the cases, polyadenylated. Similar to mRNAs, lncRNAs are also m^6^A methylated and the levels of m^6^A residues strongly depend on the cell line, tissue type and growth condition ([@B48]; [@B23]; [@B74]). In cell lines, the enrichment score of m^6^A peaks within mRNAs and lncRNAs is very similar ([@B23]). However, it has been shown recently that in human fetal tissues, a lower proportion of lncRNA is m^6^A modified compared to mRNA ([@B74]). In contrast to mRNAs, m^6^A residues in lncRNAs are distributed along the whole body of the transcript and are more present in lncRNAs that undergo alternative splicing ([@B74]). Thus, this indicates a possible function for m^6^A modification in regulation of lncRNA isoforms. Many lncRNAs are retained and function in the nucleus. Nuclear lncRNA may regulate gene expression by several mechanisms, such as modulating the activity of regulatory protein complexes, regulating chromosomal conformations and, more generally, nuclear organization (reviewed in [@B19]). In particular, different lncRNAs regulate gene expression by guiding regulatory complex to specific gene *loci*. This is generally achieved by lncRNA interaction with chromatin associated proteins, local chromosomal architecture or by forming an RNA-DNA triple helix ([@B19]; [@B39]). LncRNA local structure and interaction with specific proteins plays an important role in lncRNA function. Therein, m^6^A modification might regulate lncRNA function by providing binding sites for m^6^A reader proteins or, alternatively, might regulate local RNA structure to allow access for specific RNA-binding proteins to nearby m^6^A residues. Furthermore, m^6^A modification may also influence RNA--DNA triple helix formation, in which a lncRNA binds with sequence specificity through Hoogsteen base pairs in the major groove of a Watson--Crick base-paired DNA duplex. Therein, m^6^A modification can potentially affect lncRNA interaction with specific DNA *loci*.

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), also known as nuclear-enriched abundant transcript 2 (NEAT2), is a highly expressed nuclear lncRNA, frequently upregulated in cancer, that contains several m^6^A modifications ([@B14]). Even if MALAT1 is transcribed by RNA pol II, it lacks a canonical poly-A tail. The high stability observed for MALAT1 transcript is ensured by a triple-helix at its 3′-end that specifically binds METTL16 ([@B7], [@B8]). MALAT1 accumulates in the nuclear speckels, which are nuclear domains enriched in splicing factors, and associates with different splicing regulators such as the serine/arginine-rich (SR) proteins and the protein heterogeneous nuclear ribonucleoprotein C ([@B63]; [@B86]). In cell lines, MALAT1 silencing alters the alternative splicing of specific pre-mRNAs ([@B63]). However, MALAT1 knock-out in mouse has no effect on the alternative splicing nor on the formation of nuclear speckles ([@B52]; [@B81]). A further study showed that MALAT1 can also bind to the Polycomb 2 protein (Pc2), a component of the Polycomb Repressive Complex -1 (PRC1), and that it can act as scaffold in distinct subnuclear compartments required for coordinated regulation of gene transcription ([@B77]). Notably, m^6^A modifications identified in MALAT1 can alter the accessibility of the RNA motif to which proteins bind, through changing its local structure ([@B42]; [@B62]; [@B86]), a mechanism known as "m^6^A switch" ([@B42]). Therein, m^6^A might affect the function of MALAT1 in splicing and transcription by regulating RNA-protein interactions.

MALAT1 can also interact with microRNAs and act as a competing endogenous RNA (ceRNA), thus affecting microRNA binding to target mRNAs, in different cell types ([@B37]; [@B22]; [@B24]; [@B73]). Even in some cases, the interaction of MALAT1 with microRNAs has been reported to occur in the nucleus ([@B37]), whereas in other cases, a specific translocation of MALAT1 in the cytoplasm is required ([@B22]). However, the mechanism responsible for its translocation is still not known. Notably, m^6^A modification is directly involved in RNA nuclear export ([@B85]; [@B58]; [@B36]). Therein, the level of m^6^A modifications within MALAT1 might directly control its cellular localization and, eventually, its ceRNA activity. Alternatively, m^6^A modifications might directly regulate the RNA-RNA interactions between MALAT1 and targeted microRNAs, as recently reported for another ceRNA ([@B76]).

The X-inactive specific transcript (Xist), an important regulator of X-chromosome inactivation in mammals, is another highly m^6^A methylated lncRNA. An initial shRNA screening performed in mESCs identified three components of the MACOM complex, WTAP, VIRMA (also known as KIAA1429) and RBM15 proteins, which are all regulators of Xist activity ([@B50]). Moreover, knockdown of RBM15 and WTAP greatly impaired Xist mediated epigenetic silencing ([@B50]). In addition, WTAP protein was also identified as a stable interactor of Xist RNA ([@B11]). More recently, it has been confirmed that m^6^A modification is strictly required for Xist-mediated transcriptional repression and that knockdown of the METTL3 writer inhibits X chromosome silencing ([@B53]). The RBM15 protein was identified as the MACOM components that interacts with and guides the METTL3/METTL14 complex for the formation of the 78 m^6^A present in Xist RNA ([@B53]). Furthermore, it was also shown that the YTHDC1 reader recognized the m^6^A marks in mESCs and is required for Xist activity even if the mechanism has not yet been clarified ([@B53]). Notably, tethering of YTHDC1 on Xist in the absence of m^6^A residues is sufficient for its repressive function, indicating that m^6^A *per se* is not required for Xist activity. YTHDC1 is the only nuclear reader of the YTH family and is usually involved in the regulation of pre-mRNA spicing through recruiting splicing factors ([@B75]). Similarly, YTHDC1 binding on Xist might function by bridging *cis*- acting regulatory elements on XIST RNA with *trans*-acting proteins required for transcriptional silencing.

Recently, it has also been found that the enhancer RNAs (eRNAs), non-coding transcripts produced from enhancer regions that act as regulators of transcription, are highly m^6^A modified ([@B74]). This has suggested that m^6^A modification might contribute to the enhancer function of eRNAs during transcription.

In the cytoplasm, lncRNAs may regulate mRNA stability and translation by recruiting regulatory proteins to interacting mRNAs or by acting as ceRNAs (reviewed [@B20]). Therein, m^6^A residues might affect cytoplasmic lncRNA function with the same mechanisms described above. A recently identified cytoplasmic lncRNA whose function is regulated by m^6^A is lincRNA 1281 (linc1281) ([@B76]). Linc1281 is required for mESC differentiation and acts as a ceRNA by sequestering miRNAs of the let-7 family ([@B76]). Notably, linc1281 contains different m^6^A marks in its 3′-end region that are required for the binding of let-7 ([@B76]). It has been proposed that the presence of m^6^A in linc1281 can act as m^6^A-switch for specific RNA binding proteins, which will eventually regulate the interaction with let-7. However, the identity of such proteins has not yet been discovered. A similar mechanism has been already proposed for the binding of HuR (ELAVL1) protein and miRNAs to mRNAs encoding developmental regulators in mESCs (see below).

In view of the fact that many lncRNAs can be m^6^A modified and that m^6^A can affect their expression levels and functions, it very likely that other examples of lncRNAs regulated by m^6^A modification will follow soon.

Interplay Between Non-Coding RNAs and m^6^A Effector Proteins {#S4}
=============================================================

As highlighted above, m^6^A is a relevant modification for non-coding RNA biogenesis and functional activity. However, it has been also reported that lncRNAs may control the function of the epitranscriptomics machinery. For example, the expression of the nuclear lncRNA FOXM1-AS allows the interaction between the FOXM1 nascent RNA and the m^6^A demethylase ALKBH5, that results in the demethylation of FOXM1 transcripts. This promotes the binding of HuR protein (also known as ELAVL1) with FOXM1 pre-mRNA, resulting in an elevated expression of FOXM1. Interestingly, it has also been shown that, in glioblastoma stem-like cells (GSCs), the m^6^A demethylase ALKBH5 is highly expressed, and the depletion of ALKBH5 and FOXM1-AS disrupts GSC tumorigenesis through the reduction FOXM1 expression ([@B83]) ([Figure 2A](#F2){ref-type="fig"}).

![Examples of the interplay between non-coding RNAs and epitranscriptomics. **(A)** In glioblastoma stem-like cells (GSCs) the expression of FOXM1 is increased by the concomitant expression of the antisense transcript FOXM1-AS, which, in turn, promote m^6^A demethylation by recruiting ALKBH5 ([@B83]). **(B)** m^6^A RNA methylation is positively regulated by microRNAs, which recruit METTL3 on specific mRNA and promotes reprogramming to pluripotency ([@B10]). **(C)** m^6^A modification decreases the IGFBP3 mRNA levels by inhibiting the binding of HuR and promoting the interaction with microRNAs. IGFBP3 protein positively regulates the stability of different developmental regulators. This mechanism ensures low level of IGFBP3 in mESCs ([@B66]).](fcell-07-00116-g002){#F2}

Recently, an additional function of non-coding RNAs in the control of m^6^A modification has emerged. In particular, it has been reported that the expression of epitranscriptomics machinery components may be controlled by miRNAs through the targeting of their corresponding mRNAs. Here, we include some representative examples of such modulation.

miR-145, broadly reported as a tumor suppressor miRNA, was shown to control the expression of the YTHDF2 reader. YTHDF2 is involved in the deadenylation and decay of m^6^A-containing RNAs through a direct interaction and recruitment of the CCR4-NOT deadenylase complex ([@B15]).

Specifically, in liver cancer cells, miR-145 downregulates YTHDF2 mRNA expression with an increase on the overall levels of mRNAs containing m^6^A residues, as evaluated by dot-blot and immunofluorescence analyses with anti m^6^A antibodies, which do not allow m^6^A mapping in specific RNA species ([@B78]). Interestingly, this increase is inhibited by YTHDF2 overexpression, supporting the central role of this protein in this regulation ([@B78]). Accordingly, miR-145 expression levels are negatively correlated with those of YTHDF2 in HCC tissues. Functionally, miR-145 is able to suppresses the proliferation of HCC cells through the modulation of m^6^A-modified mRNA levels by targeting the 3′-UTR of YTHDF2 mRNA.

Another example is represented by miR-33a. In non-small-cell lung carcinoma (NSCLC) cells, it was recently described that miR-33a, by targeting the 3′-UTR of METTL3 mRNA, reduces the expression of METTL3 at both mRNA and protein levels and, eventually, global m^6^A mRNA methylation, with a functional reduction of cellular proliferation and anchorage-independent growth ([@B16]).

Recently, it has been reported that the oncogenic properties of glioblastoma stem cells (GSCs) in terms of proliferation, migration, and invasion could be influenced by a novel miR-29a/QKI-6/WTAP molecular axis ([@B72]). Of note, the overexpression of miR-29a inhibits WTAP expression and the activation of the ERK and PI3K/AKT pathways by downregulating QKI-6 expression and impairing the oncogenic abilities of GSCs ([@B72]). The impact of this regulatory network on m^6^A levels have not been addressed in this study. However, considering the relevance of WTAP in regulating the methylation activity of the METTL3-METTL14 complex ([@B57]), it might be speculated that miR-29a, besides regulating DNA methylation during cell reprograming by targeting DNA-methyl-transferases (DNMTs) ([@B28]), could also have a crucial role in the modulation of RNA m^6^A methylation during neoplastic transformation processes.

Lately, a novel role of miRNAs in the regulation of m^6^A modification has emerged. Specifically, an enrichment of seed sequences for miRNAs has been observed in transcripts presenting m^6^A residues using next generation sequencing (NGS) approaches ([@B10]). This study evaluated the contribution of miRNAs to the *ab initio* induction of m^6^A methylation by depletion or overexpression of Dicer to modulate the overall miRNAs activity. In particular, Dicer expression favors the induction of m^6^A methylation on target mRNAs, highlighting the tight connection between miRNAs activity and m^6^A modification. Mechanistically, Dicer promotes the localization of METTL3 in nuclear speckles, enhancing its interaction with the transcript subjected to m^6^A modification. In the same study, by using m^6^A-Seq, the authors identified m^6^A levels specific to different degrees of pluripotency by analyzing various experimental models, such as ESCs, induced pluripotent stem cells (iPSCs), neural stem cells (NSCs), and testicular sertoli cells (SCs). They revealed the existence of both cell-common and cell-specific modified transcripts associated with biological processes such as stem cell maintenance and cell differentiation. Moreover, to explore the contribution of m^6^A modification in cell reprograming, the authors overexpressed human METTL3 into mouse embryonic fibroblasts (MEFs), expressing the reprograming factors Oct4, Sox2, Klf4, and c-Myc, and evidenced that the reprograming efficiency of MEFs was significantly improved by the increase METTL3-dependent m^6^A levels ([@B10]) ([Figure 2B](#F2){ref-type="fig"}).

Of note, a role for m^6^A as a signal for miRNA-dependent degradation of transcripts encoding developmental regulators in mESCs has also recently emerged. Indeed, during mESCs normal development, the METTL3/METTL14-dependent m^6^A methylation of transcripts encoding developmental regulators blocks HuR protein binding and results in miRNAs-mediated transcript destabilization ([@B66]). The loss of m^6^A modification, in METTL3 and METTL14 knocked-down cells, allows for HuR-mRNA interaction and reduction of miRNA functional activity, improving transcripts stability and promoting loss of the mESC ground state ([@B66]) ([Figure 2C](#F2){ref-type="fig"}).

On the contrary, it has also been shown that the presence of m^6^A modification may serve as a protective signal, which inhibits mRNA degradation through the binding of the IGF2BPs readers. In the case of SRF transcript, m^6^A modification allows interaction with IGF2BP inhibiting miRNA-mediated decay in cancer cells ([@B51]). SRF induction is associated with tumor cell phenotype and poor prognosis (Muller et al., 2019). In addition, IGF2BP1 can also stabilize different oncogenic mRNAs by inhibiting general mRNA degradation, as reported for MYC mRNA ([@B26]).

Conclusion {#S5}
==========

We are witnessing an impressive increase in the number of studies elucidating the role of m^6^A modification in cell development and cancer. However, the majority of these studies mainly focused on the impact of m^6^A marks on coding RNAs, while an important contribution of ncRNA molecules is emerging, such as lncRNAs and microRNAs, on the function of the epitranscriptome. Moreover, lncRNA and miRNA function can be itself regulated by m^6^A. Nevertheless, different questions still need to be answered. In particular, mapping of m^6^A modification in mRNAs and lncRNAs showed a different distribution of m^6^A marks within these two types of RNA pol II transcripts. However, it is still not known how this is achieved and, above all, if specific regulatory factors act differentially in controlling the m^6^A methylases activity on mRNA and lncRNA molecules. Moreover, these studies have mainly used polyA^+^ RNA for m^6^A mapping, therein excluding many regulatory ncRNAs missing a polyA tail. Other important remaining questions in the field will be to determine if small ncRNAs such as miRNAs or the recently functionally characterized Y RNAs contain m^6^A residues and if these are relevant for their regulatory function in normal and pathological conditions. Furthermore, another important issue concerns the impact of the interplay between m^6^A modification and non-coding RNA molecules on cell fate determination and development, and which are relevant for these biological processes. In this review, we have described some examples, but the general impact of this emerging molecular network will be clarified after extensive further investigation.
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